ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

INCHEON, South Korea--(BUSINESS WIRE)--A new post-hoc analysis of a pivotal phase III randomised controlled clinical trial shows that the subcutaneous (SC) formulation of infliximab, Remsima ® (CT-P13 ...

Aggressive infliximab dosing regimens – intensified induction or accelerated induction – show similar clinical responses and remission rates as the standard infliximab dosing approach in patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients who received Remicade for inflammatory bowel ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...

Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, ...

One-fourth of patients who switched to an infliximab biosimilar retransitioned back to the originator, but they were more likely to subsequently discontinue treatment due to an unwanted response after ...